Armour Thyroid vs Tirosint: Cost, Access, and Clinical Comparison

What Are These Two Drugs?

Armour Thyroid is a natural desiccated thyroid (NDT) product derived from porcine thyroid glands. Each grain (60 mg) contains approximately 38 mcg of levothyroxine (T4) and 9 mcg of liothyronine (T3), along with trace amounts of T1, T2, and calcitonin [1]. The drug has been available since the early 1900s, predating the FDA approval process, and was later granted formal approval.

Tirosint takes a fundamentally different approach. It delivers synthetic levothyroxine (T4 only) inside a liquid-filled gel capsule that contains just three inactive ingredients: gelatin, glycerin, and water [2]. This minimal excipient profile sets it apart from standard levothyroxine tablets, which contain fillers, dyes, and binding agents that can interfere with absorption in certain patients. The American Thyroid Association (ATA) recommends levothyroxine as the standard treatment for hypothyroidism, though it acknowledges that combination T4/T3 therapy may benefit a subset of patients [3].

These two medications occupy very different niches. Armour Thyroid appeals to patients and providers who prefer combination hormone replacement or a "natural" source. Tirosint targets those who struggle with absorption issues or react to the inactive ingredients in conventional levothyroxine tablets.

Clinical Efficacy: What the Trials Show

No randomized controlled trial has directly compared Armour Thyroid to Tirosint. The best available evidence comes from separate studies evaluating each drug against standard levothyroxine tablets.

Hoang et al. (2013) conducted a double-blind, randomized crossover trial (N=70) comparing desiccated thyroid extract to levothyroxine over two 16-week treatment periods [1]. Both therapies achieved similar TSH normalization. Patients on desiccated thyroid lost an average of 1.5 kg more than those on levothyroxine (P = 0.02). About 49% of participants preferred desiccated thyroid, compared to 19% who preferred levothyroxine (P = 0.001). Free T4 levels were lower and free T3 levels were higher during the desiccated thyroid phase, as expected from the T3 content. The study concluded that both treatments controlled TSH equally well, but patient preference favored NDT.

Vita et al. (2014) evaluated liquid levothyroxine (the same formulation concept behind Tirosint) against standard levothyroxine tablets in patients with impaired gastric absorption [4]. Patients who could not achieve target TSH on tablet levothyroxine showed improved and more consistent TSH control after switching to the liquid formulation. The study demonstrated particular benefit in patients taking proton pump inhibitors, those with atrophic gastritis, and those with lactose intolerance.

Dr. Antonio Bianco, a professor of medicine at the University of Chicago and a leading researcher in thyroid hormone biology, has stated: "Some patients feel better on desiccated thyroid, and we should not dismiss that. But the T3 component introduces variability that requires careful monitoring" [5]. This observation captures the central tension: NDT provides something synthetic T4-only products do not, but that same something demands more clinical attention.

Cost Comparison: Retail, Insurance, and Out-of-Pocket

Cost drives real-world medication choices as much as clinical data does. The price gap between these two drugs depends heavily on insurance status and pharmacy selection.

Without insurance, Armour Thyroid (60 mg, 30 tablets) typically costs $30 to $90 at retail pharmacies in the United States. Pricing varies by region and pharmacy, and discount programs like GoodRx can reduce costs to $20 to $50 in many markets. Generic NDT alternatives such as NP Thyroid (Acella Pharmaceuticals) may cost even less, though FDA recalls have intermittently affected supply.

Tirosint (13 mcg to 200 mcg, 30 gel caps) costs approximately $50 to $130 per month at retail without insurance. No AB-rated generic exists for the gel cap formulation, which keeps prices higher. Tirosint-SOL, a liquid solution version, carries a similar price point. Manufacturer savings programs through IBSA Pharma can reduce copays to as low as $25 per month for commercially insured patients.

Insurance coverage introduces another variable. Many formularies place Armour Thyroid in a non-preferred tier or exclude it entirely, requiring prior authorization or step therapy through generic levothyroxine first. The ATA's 2014 guidelines favor levothyroxine monotherapy as first-line, and insurers use this recommendation to justify coverage restrictions on NDT products [3]. Tirosint generally lands on Tier 3 of commercial formularies, making it accessible but at a higher copay than generic levothyroxine tablets (Tier 1, often $4 to $15 per month).

For patients paying entirely out of pocket, Armour Thyroid is usually the less expensive option. For those with commercial insurance, the relative cost depends on specific plan design.

Absorption and Bioavailability Differences

The formulation differences between these drugs matter most in patients with gastrointestinal conditions. Standard levothyroxine tablets require an acidic gastric environment for dissolution and absorption. Conditions that reduce stomach acid, including atrophic gastritis, H. pylori infection, and chronic PPI use, can impair tablet absorption by 20% to 40% [6].

Tirosint's gel cap bypasses this problem. The levothyroxine is already dissolved in the capsule, so absorption does not depend on gastric acid. Vita et al. demonstrated that patients who failed to reach target TSH on tablets achieved stable levels after switching to liquid levothyroxine [4]. This makes Tirosint a strong choice for patients on omeprazole, pantoprazole, or other PPIs that suppress gastric acid.

Armour Thyroid is a compressed tablet. Its absorption profile has not been studied as extensively in malabsorptive populations. Patients taking Armour Thyroid with calcium supplements, iron, or coffee may experience the same absorption interference seen with standard levothyroxine tablets. The FDA labeling for all thyroid hormone products recommends dosing on an empty stomach, 30 to 60 minutes before food.

One practical consideration: Tirosint does not contain lactose, gluten, dye, or sugar. Patients with celiac disease or dye allergies (particularly those sensitive to FD&C dyes found in color-coded levothyroxine tablets) may find Tirosint preferable for tolerability alone.

The T3 Question: Does It Matter?

The most significant pharmacological difference between these two drugs is T3. Armour Thyroid provides it. Tirosint does not.

Healthy thyroid glands produce T4 and T3 in a ratio of approximately 14:1 to 20:1. Peripheral tissues convert T4 to T3 through deiodinase enzymes, supplying most of the body's active thyroid hormone. In most patients, levothyroxine monotherapy supplies enough T4 for adequate T3 conversion. But a subset of patients carry polymorphisms in the DIO2 gene (encoding type 2 deiodinase) that may impair this conversion [7]. The 2012 study by Panicker et al. found that patients with DIO2 polymorphisms reported worse psychological well-being on levothyroxine alone compared to combination therapy.

For patients who genuinely need exogenous T3, Armour Thyroid provides a fixed-ratio combination. The T4:T3 ratio in NDT (approximately 4.2:1) is much lower than the ratio the human thyroid produces. This means patients on Armour Thyroid often have higher free T3 and lower free T4 levels than their natural physiology would produce. Some clinicians view this as a drawback; others see it as a therapeutic feature.

The European Thyroid Association has noted that while routine combination therapy is not supported by large-scale RCTs, individual patients may benefit, and further research including pharmacogenomic stratification is warranted [8]. Tirosint, as a T4-only product, does not address the T3 conversion question at all. Patients who want combination therapy while using Tirosint would need to add a separate liothyronine (Cytomel) prescription, increasing both complexity and cost.

Switching Between Armour Thyroid and Tirosint

Patients can switch between these medications under clinician supervision. The switch is not milligram-to-milligram.

One grain (60 mg) of Armour Thyroid contains approximately 38 mcg of T4 and 9 mcg of T3. Because T3 is roughly three to four times more potent than T4 on a microgram basis, one grain of Armour Thyroid is approximately equivalent to 75 to 100 mcg of levothyroxine [3]. A patient on 2 grains (120 mg) of Armour Thyroid would start at roughly 150 to 200 mcg of Tirosint, with the dose adjusted based on TSH and free T4 levels checked at 6 to 8 weeks.

Switching from Tirosint to Armour Thyroid requires the reverse calculation, plus awareness that the patient will now receive T3. Starting at a slightly lower equivalent dose and titrating upward is safer, particularly in older patients or those with cardiac history. The ATA guidelines recommend checking TSH 4 to 8 weeks after any thyroid medication change [3].

Dr. Elizabeth Pearce, an endocrinologist at Boston Medical Center and former Secretary of the American Thyroid Association, has advised: "When switching thyroid preparations, I recheck TSH in six weeks and counsel patients that symptom stabilization may take eight to twelve weeks" [9]. Patients should not adjust doses independently during this transition period.

Access Challenges and Supply Considerations

Both medications have faced access disruptions in recent years, though for different reasons.

Armour Thyroid experienced intermittent supply shortages between 2019 and 2022, driven in part by manufacturing constraints at AbbVie's production facilities. During these shortages, patients scrambled for alternatives or switched to NP Thyroid, which later faced its own FDA recall in 2020 due to superpotent tablets containing up to 115.5% of the labeled T3 amount. These supply chain issues underscored a persistent vulnerability in the NDT market: fewer manufacturers, less production redundancy, and higher sensitivity to disruption.

Tirosint's access challenges are primarily financial. Without insurance coverage or a manufacturer coupon, the out-of-pocket cost presents a barrier for many patients. Some insurers require documented failure on generic levothyroxine tablets before authorizing Tirosint coverage, a step therapy requirement that can delay appropriate treatment by months. Specialty pharmacies and direct manufacturer ordering can sometimes offer better pricing than retail chains.

For telehealth patients, both drugs can be prescribed through standard e-prescribing systems. Armour Thyroid and Tirosint are both Schedule VI prescription medications (non-controlled) and do not require DEA registration or special prescribing authority. Telehealth platforms that treat hypothyroidism, including HealthRX, can prescribe either medication based on clinical indication.

Who Should Consider Which Drug?

Patient selection matters more than brand loyalty. The choice between Armour Thyroid and Tirosint depends on specific clinical variables.

Tirosint is the stronger option for patients who take PPIs or H2 blockers daily, those diagnosed with celiac disease or lactose intolerance, patients who have demonstrated erratic TSH levels on tablet levothyroxine despite good adherence, and anyone with documented dye sensitivities. It is also appropriate for patients who do well on T4 monotherapy and simply need a cleaner formulation.

Armour Thyroid suits patients who have persistent symptoms (fatigue, brain fog, weight gain) despite "normal" TSH on levothyroxine monotherapy. It may benefit those with confirmed DIO2 polymorphisms that impair T4-to-T3 conversion [7]. Some patients report subjective improvement on NDT that does not correlate with measurable hormone differences. Whether this reflects a true T3 effect, a placebo response, or an as-yet-unidentified mechanism remains debated.

Neither drug is appropriate as initial therapy for thyroid cancer TSH suppression, where precise T4 dosing and consistent potency are required. The ATA's thyroid cancer guidelines recommend synthetic levothyroxine for this population [10].

Monitoring Requirements

Both drugs require the same baseline monitoring: TSH every 6 to 8 weeks during dose titration, then every 6 to 12 months once stable. Free T4 should be measured alongside TSH. Patients on Armour Thyroid also need free T3 levels checked, since the exogenous T3 component can suppress TSH while free T4 remains low, potentially masking undertreated hypothyroidism if TSH alone is monitored.

Armour Thyroid doses should be taken consistently on an empty stomach, and blood draws should occur before the daily dose (trough levels). Drawing blood 2 to 4 hours after an Armour Thyroid dose will capture a T3 spike that does not reflect the patient's average hormone status.

Tirosint monitoring follows standard levothyroxine protocols. The gel cap's consistent absorption profile tends to produce less visit-to-visit TSH variability, which simplifies dose optimization. Patients on Tirosint who are also taking biotin supplements should stop biotin at least 48 hours before thyroid lab draws, as biotin can interfere with immunoassay-based TSH and free T4 measurements [11].

Clinicians should recheck TSH 6 weeks after starting Tirosint 88 mcg (a common mid-range dose) and adjust by 12.5 to 25 mcg increments based on results.